Repligen Corporation $RGEN is Stephens Investment Management Group LLC’s 6th Largest Position

Stephens Investment Management Group LLC grew its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 9.8% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 657,111 shares of the biotechnology company’s stock after buying an additional 58,755 shares during the period. Repligen makes up 1.4% of Stephens Investment Management Group LLC’s investment portfolio, making the stock its 6th largest position. Stephens Investment Management Group LLC’s holdings in Repligen were worth $107,674,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. United Capital Financial Advisors LLC bought a new stake in shares of Repligen during the 3rd quarter valued at $368,387,000. Holocene Advisors LP boosted its holdings in shares of Repligen by 47.0% during the 3rd quarter. Holocene Advisors LP now owns 1,377,104 shares of the biotechnology company’s stock valued at $184,077,000 after buying an additional 440,290 shares in the last quarter. Massachusetts Financial Services Co. MA bought a new stake in shares of Repligen during the 4th quarter valued at $199,176,000. Alliancebernstein L.P. boosted its holdings in shares of Repligen by 21.8% during the 3rd quarter. Alliancebernstein L.P. now owns 1,104,171 shares of the biotechnology company’s stock valued at $147,595,000 after buying an additional 197,778 shares in the last quarter. Finally, Conestoga Capital Advisors LLC boosted its holdings in shares of Repligen by 10.6% during the 4th quarter. Conestoga Capital Advisors LLC now owns 1,057,975 shares of the biotechnology company’s stock valued at $173,360,000 after buying an additional 101,062 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Stock Performance

Shares of Repligen stock opened at $102.87 on Friday. Repligen Corporation has a 1 year low of $100.99 and a 1 year high of $175.77. The firm’s 50-day moving average is $118.96 and its 200 day moving average is $142.18. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78. The stock has a market cap of $5.80 billion, a price-to-earnings ratio of 114.30, a PEG ratio of 1.98 and a beta of 1.09.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The business had revenue of $194.26 million during the quarter, compared to analyst estimates of $192.05 million. During the same quarter in the previous year, the firm earned $0.39 EPS. Repligen’s revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Sell-side analysts anticipate that Repligen Corporation will post 1.99 EPS for the current fiscal year.

Analyst Ratings Changes

RGEN has been the topic of a number of research reports. Royal Bank Of Canada initiated coverage on shares of Repligen in a report on Thursday. They set an “outperform” rating and a $160.00 target price on the stock. Jefferies Financial Group restated a “hold” rating and set a $142.00 target price on shares of Repligen in a report on Tuesday, May 5th. Wall Street Zen cut shares of Repligen from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Weiss Ratings upgraded shares of Repligen from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, May 7th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $166.15.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.